These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 26365310)
21. Age-related LRRK2 G2019S Mutation Impacts Microglial Dopaminergic Fiber Refinement and Synaptic Pruning Involved in Abnormal Behaviors. Zhang Q; Cheng X; Wu W; Yang S; You H; Ye Z; Liu N; Chen X; Pan X J Mol Neurosci; 2022 Mar; 72(3):527-543. PubMed ID: 34409578 [TBL] [Abstract][Full Text] [Related]
22. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990 [TBL] [Abstract][Full Text] [Related]
23. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768 [TBL] [Abstract][Full Text] [Related]
24. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. Niu J; Yu M; Wang C; Xu Z J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965 [TBL] [Abstract][Full Text] [Related]
25. Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. Zach S; Felk S; Gillardon F PLoS One; 2010 Oct; 5(10):e13191. PubMed ID: 20949042 [TBL] [Abstract][Full Text] [Related]
26. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068 [TBL] [Abstract][Full Text] [Related]
27. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669 [TBL] [Abstract][Full Text] [Related]
28. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868 [TBL] [Abstract][Full Text] [Related]
29. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. Russo I; Di Benedetto G; Kaganovich A; Ding J; Mercatelli D; Morari M; Cookson MR; Bubacco L; Greggio E J Neuroinflammation; 2018 Oct; 15(1):297. PubMed ID: 30368241 [TBL] [Abstract][Full Text] [Related]
30. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252 [TBL] [Abstract][Full Text] [Related]
31. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2. Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245 [TBL] [Abstract][Full Text] [Related]
32. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease. Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633 [TBL] [Abstract][Full Text] [Related]
33. LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation. Ho DH; Je AR; Lee H; Son I; Kweon HS; Kim HG; Seol W Exp Neurobiol; 2018 Jun; 27(3):171-180. PubMed ID: 30022868 [TBL] [Abstract][Full Text] [Related]
35. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Caesar M; Zach S; Carlson CB; Brockmann K; Gasser T; Gillardon F Neurobiol Dis; 2013 Jun; 54():280-8. PubMed ID: 23318930 [TBL] [Abstract][Full Text] [Related]
36. The LRRK2-G2019S mutation attenuates repair of brain injury partially by reducing the release of osteopontin-containing monocytic exosome-like vesicles. An J; Yang H; Park SM; Chwae YJ; Joe EH Neurobiol Dis; 2024 Jul; 197():106528. PubMed ID: 38740348 [TBL] [Abstract][Full Text] [Related]
37. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139 [TBL] [Abstract][Full Text] [Related]